| Q55622381 | Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy. |
| Q28084979 | Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy |
| Q37725303 | Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair |
| Q26785627 | Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options |
| Q35660390 | Cardiac function in muscular dystrophy associates with abdominal muscle pathology |
| Q50058440 | Cardiac specific expression of ∆H2-R15 mini-dystrophin normalized all ECG abnormalities and the end-diastolic volume in a 23-m-old mouse model of Duchenne dilated cardiomyopathy. |
| Q94453500 | Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice |
| Q38914933 | Diaphragm degeneration and cardiac structure in mdx mouse: potential clinical implications for Duchenne muscular dystrophy |
| Q41822348 | Diastolic dysfunction precedes hypoxia-induced mortality in dystrophic mice |
| Q35399258 | Disruption of KATP channel expression in skeletal muscle by targeted oligonucleotide delivery promotes activity-linked thermogenesis |
| Q30574663 | Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery. |
| Q35086442 | Early right ventricular fibrosis and reduction in biventricular cardiac reserve in the dystrophin-deficient mdx heart. |
| Q33594805 | Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy |
| Q36670780 | Engraftment of ES-Derived Myogenic Progenitors in a Severe Mouse Model of Muscular Dystrophy |
| Q36908212 | Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy |
| Q36297940 | Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. |
| Q42071747 | From innate to adaptive immune response in muscular dystrophies and skeletal muscle regeneration: the role of lymphocytes |
| Q35821127 | How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse |
| Q41949953 | Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy. |
| Q34123466 | In vivo MRI characterization of progressive cardiac dysfunction in the mdx mouse model of muscular dystrophy. |
| Q51164233 | Low dystrophin levels in heart can delay heart failure in mdx mice. |
| Q30539986 | Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice |
| Q28546070 | Metabolic dysfunction and altered mitochondrial dynamics in the utrophin-dystrophin deficient mouse model of duchenne muscular dystrophy |
| Q91593312 | Micro-dystrophin Genes Bring Hope of an Effective Therapy for Duchenne Muscular Dystrophy |
| Q38161422 | Modifiers of heart and muscle function: where genetics meets physiology |
| Q38920803 | Murine cardiosphere-derived cells are impaired by age but not by cardiac dystrophic dysfunction. |
| Q92610563 | Natural History of Cardiomyopathy in Adult Dogs With Golden Retriever Muscular Dystrophy |
| Q34049251 | Neuronal nitric oxide synthase-rescue of dystrophin/utrophin double knockout mice does not require nNOS localization to the cell membrane |
| Q52372774 | Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics. |
| Q93138367 | Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases |
| Q30626615 | Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice |
| Q36773242 | Progress in gene therapy of dystrophic heart disease |
| Q37021623 | Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy |
| Q30514014 | Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping |
| Q41510029 | Respiratory magnetic resonance imaging biomarkers in Duchenne muscular dystrophy |
| Q41374222 | Second-generation compound for the modulation of utrophin in the therapy of DMD. |
| Q52429827 | Skipping Multiple Exons to Treat DMD-Promises and Challenges. |
| Q37909000 | Targeting RNA to treat neuromuscular disease |
| Q28069201 | Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy |
| Q36892517 | The Correlation of Skeletal and Cardiac Muscle Dysfunction in Duchenne Muscular Dystrophy |
| Q63301935 | Voluntary exercise improves muscle function and does not exacerbate muscle and heart pathology in aged Duchenne muscular dystrophy mice |
| Q35388411 | Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy |